Cancer Biomarkers Market (By Type: Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Others; By Biomolecule: Genetic Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Proteomic Biomarkers, Others; By Application: Drug Discovery and Development, Diagnostics, Personalized Medicine, Others; By Profiling Technology; By End User) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024 – 2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cancer Biomarkers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cancer Biomarkers Market, by Type, 2024-2033
8.1.1. Breast Cancer
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Prostate Cancer
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Colorectal Cancer
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Cervical Cancer
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Liver Cancer
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Lung Cancer
8.1.6.1. Market Revenue and Forecast (2021-2033)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2021-2033)
9.1. Cancer Biomarkers Market, by Biomolecule Type, 2024-2033
9.1.1. Genetic Biomarkers
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Epigenetic Biomarkers
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Metabolic Biomarkers
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Proteomic Biomarkers
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2033)
10.1. Cancer Biomarkers Market, by Application Type, 2024-2033
10.1.1. Drug Discovery and Development
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Diagnostics
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Personalized Medicine
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2021-2033)
11.1. Cancer Biomarkers Market, by Profiling Technology Type, 2024-2033
11.1.1. Omic Technologies
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Imaging Technologies
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Immunoassays
11.1.3.1. Market Revenue and Forecast (2021-2033)
11.1.4. Cytogenetics-based Tests
11.1.4.1. Market Revenue and Forecast (2021-2033)
12.1. Cancer Biomarkers Market, by End User, 2024-2033
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast (2021-2033)
12.1.2. Academic and Cancer Research Institutes
12.1.2.1. Market Revenue and Forecast (2021-2033)
12.1.3. Ambulatory Surgical Centres
12.1.3.1. Market Revenue and Forecast (2021-2033)
12.1.4. Diagnostic Laboratories
12.1.4.1. Market Revenue and Forecast (2021-2033)
13.1. North America
13.1.1. Market Revenue and Forecast, by Type (2021-2033)
13.1.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.1.3. Market Revenue and Forecast, by Application (2021-2033)
13.1.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.1.5. Market Revenue and Forecast, by End User (2021-2033)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Type (2021-2033)
13.1.6.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.1.6.3. Market Revenue and Forecast, by Application (2021-2033)
13.1.6.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.1.7. Market Revenue and Forecast, by End User (2021-2033)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Type (2021-2033)
13.1.8.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.1.8.3. Market Revenue and Forecast, by Application (2021-2033)
13.1.8.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.1.8.5. Market Revenue and Forecast, by End User (2021-2033)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Type (2021-2033)
13.2.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.2.3. Market Revenue and Forecast, by Application (2021-2033)
13.2.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.2.5. Market Revenue and Forecast, by End User (2021-2033)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Type (2021-2033)
13.2.6.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.2.6.3. Market Revenue and Forecast, by Application (2021-2033)
13.2.7. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.2.8. Market Revenue and Forecast, by End User (2021-2033)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Type (2021-2033)
13.2.9.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.2.9.3. Market Revenue and Forecast, by Application (2021-2033)
13.2.10. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.2.11. Market Revenue and Forecast, by End User (2021-2033)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Type (2021-2033)
13.2.12.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.2.12.3. Market Revenue and Forecast, by Application (2021-2033)
13.2.12.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.2.13. Market Revenue and Forecast, by End User (2021-2033)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Type (2021-2033)
13.2.14.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.2.14.3. Market Revenue and Forecast, by Application (2021-2033)
13.2.14.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.2.15. Market Revenue and Forecast, by End User (2021-2033)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Type (2021-2033)
13.3.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.3.3. Market Revenue and Forecast, by Application (2021-2033)
13.3.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.3.5. Market Revenue and Forecast, by End User (2021-2033)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Type (2021-2033)
13.3.6.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.3.6.3. Market Revenue and Forecast, by Application (2021-2033)
13.3.6.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.3.7. Market Revenue and Forecast, by End User (2021-2033)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Type (2021-2033)
13.3.8.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.3.8.3. Market Revenue and Forecast, by Application (2021-2033)
13.3.8.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.3.9. Market Revenue and Forecast, by End User (2021-2033)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Type (2021-2033)
13.3.10.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.3.10.3. Market Revenue and Forecast, by Application (2021-2033)
13.3.10.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.3.10.5. Market Revenue and Forecast, by End User (2021-2033)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Type (2021-2033)
13.3.11.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.3.11.3. Market Revenue and Forecast, by Application (2021-2033)
13.3.11.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.3.11.5. Market Revenue and Forecast, by End User (2021-2033)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Type (2021-2033)
13.4.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.4.3. Market Revenue and Forecast, by Application (2021-2033)
13.4.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.4.5. Market Revenue and Forecast, by End User (2021-2033)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Type (2021-2033)
13.4.6.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.4.6.3. Market Revenue and Forecast, by Application (2021-2033)
13.4.6.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.4.7. Market Revenue and Forecast, by End User (2021-2033)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Type (2021-2033)
13.4.8.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.4.8.3. Market Revenue and Forecast, by Application (2021-2033)
13.4.8.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.4.9. Market Revenue and Forecast, by End User (2021-2033)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Type (2021-2033)
13.4.10.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.4.10.3. Market Revenue and Forecast, by Application (2021-2033)
13.4.10.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.4.10.5. Market Revenue and Forecast, by End User (2021-2033)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Type (2021-2033)
13.4.11.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.4.11.3. Market Revenue and Forecast, by Application (2021-2033)
13.4.11.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.4.11.5. Market Revenue and Forecast, by End User (2021-2033)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Type (2021-2033)
13.5.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.5.3. Market Revenue and Forecast, by Application (2021-2033)
13.5.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.5.5. Market Revenue and Forecast, by End User (2021-2033)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Type (2021-2033)
13.5.6.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.5.6.3. Market Revenue and Forecast, by Application (2021-2033)
13.5.6.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.5.7. Market Revenue and Forecast, by End User (2021-2033)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Type (2021-2033)
13.5.8.2. Market Revenue and Forecast, by Biomolecule (2021-2033)
13.5.8.3. Market Revenue and Forecast, by Application (2021-2033)
13.5.8.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)
13.5.8.5. Market Revenue and Forecast, by End User (2021-2033)
14.1. F. Hoffmann-La Roche Ltd.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Thermo Fisher Scientific Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. QIAGEN N.V.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Illumina Inc.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Bio-Rad Laboratories Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Abbott Laboratories
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Exact Sciences
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Meso Scale Diagnostics LLC
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Seegene Technologies Inc.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Siemens Healthineers
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client